Trial Profile
Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy (CC-5013-MEL-003)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Nov 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Adverse reactions
- 11 Aug 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 11 Aug 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
- 07 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.